254 related articles for article (PubMed ID: 33449875)
21. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
[TBL] [Abstract][Full Text] [Related]
22. Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.
Guengerich FP; Wilkey CJ; Phan TTN
J Biol Chem; 2019 Jul; 294(28):10928-10941. PubMed ID: 31147443
[TBL] [Abstract][Full Text] [Related]
23. Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.
Lee JY; Kang NS; Kang YK
Biopolymers; 2012 Apr; 97(4):219-28. PubMed ID: 22113809
[TBL] [Abstract][Full Text] [Related]
24. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
[TBL] [Abstract][Full Text] [Related]
25. Amino acid 305 determines catalytic center accessibility in CYP3A4.
Fowler SM; Riley RJ; Pritchard MP; Sutcliffe MJ; Friedberg T; Wolf CR
Biochemistry; 2000 Apr; 39(15):4406-14. PubMed ID: 10757990
[TBL] [Abstract][Full Text] [Related]
26. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.
Murai K; Yamazaki H; Nakagawa K; Kawai R; Kamataki T
Xenobiotica; 2009 Nov; 39(11):795-802. PubMed ID: 19845430
[TBL] [Abstract][Full Text] [Related]
27. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
28. Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution.
Chuo SW; Liou SH; Wang LP; Britt RD; Poulos TL; Sevrioukova IF; Goodin DB
Biochemistry; 2019 Sep; 58(37):3903-3910. PubMed ID: 31456404
[TBL] [Abstract][Full Text] [Related]
29. Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
Isin EM; Guengerich FP
J Biol Chem; 2007 Mar; 282(9):6863-74. PubMed ID: 17200113
[TBL] [Abstract][Full Text] [Related]
30. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
31. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
Samuels ER; Sevrioukova IF
Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
Akiyoshi T; Saito T; Murase S; Miyazaki M; Murayama N; Yamazaki H; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Dispos; 2011 Apr; 39(4):724-8. PubMed ID: 21212239
[TBL] [Abstract][Full Text] [Related]
33. Drug-drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4.
Sadeghi SJ; Ferrero S; Di Nardo G; Gilardi G
Bioelectrochemistry; 2012 Aug; 86():87-91. PubMed ID: 22480862
[TBL] [Abstract][Full Text] [Related]
34. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
[TBL] [Abstract][Full Text] [Related]
36. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
37. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
38. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
39. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates.
Yamazaki H; Ueng YF; Shimada T; Guengerich FP
Biochemistry; 1995 Jul; 34(26):8380-9. PubMed ID: 7599128
[TBL] [Abstract][Full Text] [Related]
40. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
